<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>10</volume><submitter>Skovgaard L</submitter><pubmed_abstract>&lt;h4>Background and aim&lt;/h4>Self-care technologies may support patients with multiple sclerosis (MS) in their everyday disease management by enabling self-monitoring of various health indicators, such as symptom levels and physical activity levels. The aim of this study was to assess the usefulness of tracking self-selected MS- and health-related measures via a digital self-tracking tool for people with MS (PwMS) over a period of six weeks.&lt;h4>Methods&lt;/h4>An initial development phase was followed by a six-week testing phase with 58 test participants. The evaluation phase followed a sequential, exploratory mixed-methods design, consisting of 14 interviews with test participants during the testing phase, followed by a survey of all participants after the testing phase to confirm and elaborate</pubmed_abstract><journal>Digital health</journal><pagination>20552076241264389</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11301736</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Perceived usefulness of digital self-tracking among people with multiple sclerosis.</pubmed_title><pmcid>PMC11301736</pmcid><pubmed_authors>Skovgaard L</pubmed_authors><pubmed_authors>Steenberg JL</pubmed_authors><pubmed_authors>Lynning M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Perceived usefulness of digital self-tracking among people with multiple sclerosis.</name><description>&lt;h4>Background and aim&lt;/h4>Self-care technologies may support patients with multiple sclerosis (MS) in their everyday disease management by enabling self-monitoring of various health indicators, such as symptom levels and physical activity levels. The aim of this study was to assess the usefulness of tracking self-selected MS- and health-related measures via a digital self-tracking tool for people with MS (PwMS) over a period of six weeks.&lt;h4>Methods&lt;/h4>An initial development phase was followed by a six-week testing phase with 58 test participants. The evaluation phase followed a sequential, exploratory mixed-methods design, consisting of 14 interviews with test participants during the testing phase, followed by a survey of all participants after the testing phase to confirm and elaborate</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Jan-Dec</publication><modification>2026-05-04T06:37:06.185Z</modification><creation>2026-04-22T03:09:50.691Z</creation></dates><accession>S-EPMC11301736</accession><cross_references><pubmed>39108251</pubmed><doi>10.1177/20552076241264389</doi></cross_references></HashMap>